Harrow Q2 revenue slightly beats estimates

Harrow

10/08/2026 21:19

Overview
Ophthalmic drug maker's Q2 revenue rose 11% yr/yr, slightly beating analyst expectations
Company posted net loss per share of $0.46, down from profit last year

Outlook
Harrow reiterates 2026 revenue guidance of $350 mln to $365 mln
Company maintains 2026 adjusted EBITDA forecast of $80 mln to $100 mln
TYRVAYA acquisition expected to contribute modestly to 2026 revenue

Result Drivers
PRODUCT DEMAND - Co said strong demand for VEVYE, IHEEZO, and TRIESENCE drove Q2 revenue growth
EXPANDED COVERAGE - VEVYE gained expanded formulary coverage with a top-three national commercial pharmacy benefit manager, effective August 1, supporting further market share growth

Company press release: ID:nGNX3shfqG

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Beat*
$70.70 mln
$70.34 mln (8 Analysts)
Q2 Loss Per Share
 
$0.46
 
Q2 Gross Margin
 
71.00%
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Harrow, Inc. is $60.00, about 48.4% above its August 7 closing price of $40.44
The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 34 three months ago

Reuters Recommended Reads
Aug 10 - Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Aug 10 - Cogent Biosciences Q2 net loss widens on higher expenses
Aug 10 - Tenax heart drug fails to improve walking results in study, shares plunge

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)